Research programme: kidney function stem cell therapeutics - Gambro/Nephrogen LLC
Latest Information Update: 11 Sep 2013
At a glance
- Originator Gambro; Nephrogen LLC
- Developer Gambro; Nephrogen
- Class
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Kidney disorders
Most Recent Events
- 01 Nov 2009 Discontinued - Preclinical for Kidney disorders in Germany and Sweden (unspecified route)
- 01 Nov 2008 No development reported - Preclinical for Kidney disorders in Germany and Sweden (unspecified route)
- 08 Nov 2005 Preclinical trials in Kidney disorders in Germany (unspecified route)